Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “IOTHALAMIC ACID”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,585 records · Page 88Linked to original sources
PubMedDate not supplied

Comparison of blood-brain barrier disruption by intracarotid iopamidol and methylglucamine iothalamate.

Using a canine model, the effect of intracarotid injections of the ionic contrast medium methylglucamine iothalamate was compared with that of the nonionic contrast medium iopamidol of similar iodine concentration (280 mg 1/ml). The degree and distribution of blood-brain barrier disruption was assessed using Evans blue stain as a visual marker and by contrast enhancement measured by a computed tomographic (CT) scanner. In all studies with methylglucamine iothalamate, Evans blue staining was demonstrated, and CT enhancement demonstrated a significant mean difference (p less than 0.01) between the control and injected hemispheres. The absence of blood-brain barrier disruption with iopamidol is probably related to its lower osmolality (570 mosmol/kg) compared with methylglucamine iothalamate (1,424 mosmol/kg) and the absence of any cation.

Animals↗
PubMedDate not supplied

Brain parenchyma penetration by intrathecal nonionic iopamidol.

Iopamidol, a nonionic, water-soluble contrast medium, has been recently recommended for myelography. As with other such media, the extent of parenchymal penetration is of interest in relation to the genesis of clinical complications. In this study the degree and depth of brain penetration of intrathecal iopamidol, using an iodine concentration of 280 mg l/ml, were compared at 15 and 60 min in adult greyhound dogs using coronal computed tomographic scanning of the brain after removal. A significant but patchy penetration corresponding to the cortical sulci was demonstrated at 15 min, while by 60 min there had been a further increase in the distribution and concentration of the contrast medium. Comparing the present study with a previous series using metrizamide and methylglucamine iothalamate at a similar iodine concentration (280 mg l/ml), no significant difference in the depth or degree of penetration at 60 min was found between the three contrast media, indicating a similar rate of diffusion across the cerebrospinal fluid/brain interface. Therefore, any difference in neurotoxicity is not explained by a reduced concentration of contrast medium due to variation in the rate of diffusion across this interface.

Animals↗
PubMedDate not supplied

Neurotoxicity of nonionic iodinated water-soluble contrast media in myelography: experimental study.

The neurotoxicity of four contrast media--iotrol, iopamidol, metrizamide, and ioglunide--was studied by subarachnoid injection in 14 rabbits implanted with four cerebral electrodes. Thirty-four recordings and quantitative analyses were carried out of spontaneous electrical brain activity, seizure activity, and visual- and somatosensory-evoked potentials. The quantitative study of the electroencephalograms showed differences among the four products. All four of the contrast media induced a general slowing of the electroencephalographic activity and, 30 min after injection, slow waves and a shift of the spectrum energy toward the slow frequencies (0.5-3.5 Hz). The slowing of the recording was the least marked with iotrol and recovery of a normal recording was also quickest with iotrol. The quantitative study of electrical seizures and paroxysms revealed higher seizure activity with ioglunide and iopamidol. The study of the evoked potentials does not permit any distinction among the four contrast agents. Metrizamide induced the fewest seizures, but, considering the slow waves and the seizures, iotrol appears to be the least neurotoxic.

Animals↗
PubMedDate not supplied

Safety of contrast media in cerebral angiography: iopamidol vs. methylglucamine iothalamate.

A randomized double-blind study was performed in 27 patients to compare the clinical safety, incidence of pain and warmth, and film quality produced by iopamidol and Conray-60 in selective cerebral angiography. No complications or adverse reactions occurred in either group. Iopamidol was significantly less painful than was methylglucamine iothalamate for common carotid artery injections and caused significantly less heat in both common carotid and internal carotid artery injections. Film quality and diagnostic accuracy were excellent in both groups. These results, when viewed in conjunction with laboratory data demonstrating the decreased neurotoxicity of nonionic contrast agents, suggest that iopamidol is an important advance in the development of angiographic contrast media.

Adult↗
PubMedDate not supplied

[Clinical radicular symptoms in lumbosacral pain studies by radiculography with Dimer X].

Two hundred patients with low-back pain syndrome were studied. The results of neurological examination were compared with those of radiculography in these cases. It was found that although herniation of the nucleus pulposus at the L4-5 level is twice as frequent as at the L5-S1 level, radicular signs were demonstrated in 69% caused by injury to the S1 root and in 57% by injury to the L5 root. In surgically treated cases agreement between the result of surgical exploration and the result of radiculography was demonstrated in 99.7% of cases.

Adult↗
PubMed1984

[Comparison of the acute cardiovascular side effects of iopamidol, metrizamide and amidotrizoate after intracoronary and left ventricular injections].

The acute cardiovascular side effects of iopamidol (osmolality: 0.8 osmol/kg), metrizamide (0.6 osmol/kg), and amidotrizoate (2.1 osmol/kg) during coronary arteriography (n = 30) and left ventriculography (n = 9) have been compared in anesthetized closed-chest dogs (n = 5). The influences of these contrast media on hemodynamics, coronary circulation, ECG and physicochemical properties of coronary sinus blood were evaluated. Following intracoronary injection, iopamidol and metrizamide cause positive inotropism while amidotrizoate initially induces cardiodepression. All contrast solutions lead to marked increase of myocardial blood flow. Electrocardiographic changes are greater after amidotrizoate (P less than 0.05). A fall of cationic content in coronary sinus blood is seen after each contrast medium. Amidotrizoate leads to more decrease of potassium (P less than 0.01) and both ionized and total calcium (P less than 0.001). Increase of osmolality and hydrogen ionic content is greater after amidotrizoate than after iopamidol and metrizamide (P less than 0.01). Following left ventricular injection, marked peripheral vasodilation, as seen after amidotrizoate, does not occur after low osmolality compounds. There are no significant differences between iopamidol and metrizamide in spite of the slightly higher osmolality of the former. Thus, both contrast materials should be equivalent with respect to their acute cardiovascular side effects under clinical conditions. Advantages of low osmolality radiological contrast media are discussed.

Animals↗
PubMed1984

[Central venous injection of large amounts of contrast media--advantages of a low osmolar contrast medium in experimentally-induced pulmonary hypertension].

Intravenous administration of contrast material is a prerequisite for the imaging of the cardiovascular system with computed tomography and digital subtraction techniques. Fatal side effects after intravenous contrast injection, particularly in patients with pulmonary hypertension, have been reported repeatedly. The object of this study was to compare hemodynamic side effects of a conventional, ionic contrast medium (amidotrizoate; 2.1 osmol/kg) and a modern, non-ionic compound (iopamidol; 0.8 osmol/kg) after intravenous bolus injection (1.5 ml/kg). Experiments were carried out in 10 open-chest dogs with pulmonary normotension and hypertension induced by embolisation. Under control conditions (PPA = 19.9 mm Hg) both contrast media produced marked pulmonary and peripheral vasodilation. Major effects were seen after amidotrizoate (RPULM 60.3%, RPERI 32.1% vs 72.5% and 70.4% of controls). In pulmonary hypertension (PPA = 44.2 mmHg), iopamidol had similar hemodynamic effects compared to control conditions. In contrast, amidotrizoate initially led to a significant increase in pulmonary pressure and resistance (PPA = 118.6%; RPULM = 141.7%) followed by a delayed depression of right ventricular function (dP/dt = 65.3%; PRVED = 180.9%). Resuscitation was required in 3 dogs with pulmonary hypertension after amidotrizoate injection. Because of these unfavorable hemodynamic side effects of the conventional high osmolality contrast medium in animal experiments, it can be expected that modern compounds with low osmolality pruduce smaller side effects during diognostic interventions in patients with pulmonary hypertension.

Animals↗
PubMed1984

[Enzyme determination in the urine for the evaluation of kidney tolerance of the water-soluble roentgen contrast medium iopamidol].

The renal toxicity of the ionic, very hyperosmolaric megluminamidotrizoate was compared with the toxicity of the non-ionic, slightly hypertonic iopamidol after intravenous injection of 0.7 ml/kg body weight (i.e. about 300 mg iodine/ml) in a randomized study of 20 individuals with normal kidneys. Quantitative measurements of the excretion of the enzymes, lactate dehydrogenase (LDH), alkaline phosphatase (AP), and N-acetylglucosaminidase (NAG) in 24-h urine samples, serum creatinine, and the endogeneous creatine clearance were conducted to determine the possible renal damage. All 20 subjects tolerated both contrast mediums well. Reduced renal function as measured by the creatinine blood level and the endogeneous clearance did not occur. The ionic, hyperosmolaric megluminamidotrizoate++ caused significantly elevated enzymuria of NAG, AP, and LDH (P less than 0.01) following tubular irrigation, whereas iopamidol showed no significant enzymuria. Therefore, it appears that the non-ionic contrast medium, iopamidol, is less toxic for kidneys than the ionic megluminamidotrizoate.

Acetylglucosaminidase↗
PubMed1984

[Significance of a nonionic renographic contrast medium (Iopamidol 300) in the roentgen diagnosis of the kidneys and urinary tract in children].

The ionic contrast media used so far have been associated with considerable risks in infants and children. The high osmolality of these media did not always permit a dosage sufficient for kidney imaging in the nephrographic and in the pyelographic phase. The new non-ionic contrast media have largely reduced these risks so that their general application in infants and young children should be recommended. Intravenous urographies using the non-ionic contrast medium Iopamidol 300 (Solutrast 300) were performed in 195 children aged one day to 12 years. Good to superior urograms were obtained in 85% of the investigations. No adverse reactions caused by the osmolality of the contrast media had been observed in spite of the relative high dosage. As a result of their low osmolality and non-ionic property a safe application of high doses was possible.

Child↗
PubMed1984

[Value of iopamidol in radiologic diagnosis].

The effect of the contrast medium Iopamidol/Iopamiro, Bracco (Milano) was studied in 31 patients via intravascular or intraarticular injection, as well as in experiments on dogs with 32 kidneys, employing selective angiography and histological examination. In all cases, we obtained good x-ray films showing plenty of detail, the patient tolerance being good. Blood pressure, pulse rate and UN, SGOT, and SeBi values did not show any significant change. In some cases we noticed a moderate proteinuria. In the animal experiments, the kidneys showed histological changes in two cases only which could be ascribed to the action of the contrast medium; however, even these changes were of a minimal nature and degree, and were reversible. Iopamidol was found to be a very favourable contrast medium as far as the kidneys are concerned.

Aortography↗
PubMed1984

Iopamidol for myelography--practical implications.

Iopamidol (Jopamiron 200) is a new water-soluble, non-ionic contrast medium for myelography, which recommends itself for reasons of safety, diagnostic effectiveness, economy and convenience. It has been used in a small series of 185 patients in doses of 10-15 ml and found to be highly satisfactory for myelography of the lumbosacral, thoracic and cervical regions.

Contrast Media↗
PubMed1984

Double blind study of the toxicity of intrathecal iopamidol and metrizamide in lumbar myelography.

Water-soluble contrast agents (metrizamide) provide a finer myelographic assessment of the spinal neuroanatomical structures but at the expense of some occasional toxic side effects. Iopamidol, a new non-ionic water-soluble agent, has been submitted to clinical trial by the authors in their respective institutions. The combined results indicate better tolerance to this new agent with fewer side effects and those of lesser severity.

Dizziness↗
PubMed1984

[Comparison of the side effects of urographic contrast media (iothalamate, diatrizoate, iodamide, iopamidol) within the scope of a CT study].

In 1465 patients the side effects of urographic contrast media for enhancement in CT were compared. The results show that the reaction frequency with iotalamate is 5.1%, with diatrizoate 7.0% and with iodamide 8.9%, but only 0.5% with iopamidol. The number of incidents to be expected with iopamidol is one decimal place lower. Obviously this has to do with its low osmolality. On the other hand we interpret the comparatively slightly higher incidence rate when using iodamide as a result of its higher lipophilic nature.

Adolescent↗